Physician profile
Andrew W Thayne
NPI 1669405791
$4,965.02
in general payments reported to CMS, 2019-2025
45 companies · $656 in 2025
The $656 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $472 · 2021: $975 · 2022: $929 · 2023: $671 · 2024: $637 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $774.24 | 2021-2025 | Ubrelvy, Vraylar |
| Amgen INC. | $716.23 | 2019-2025 | Prolia, Evenity, Otezla |
| Astellas Pharma US INC | $429.78 | 2019-2025 | Veozah |
| Grifols USA, LLC | $345.33 | 2019-2024 | Prolastin-C Liquid |
| Novo Nordisk INC | $309.22 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $214.07 | 2019-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $200.50 | 2021-2023 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $169.47 | 2019-2025 | Austedo Xr, Austedo |
| Glaxosmithkline, LLC. | $142.02 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $119.75 | 2019-2024 | |
| Vanda Pharmaceuticals INC. | $117.20 | 2024-2025 | Fanapt |
| Abbott Laboratories | $104.24 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.76 | 2019-2023 | Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $95.87 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.42 | 2019-2023 | Xifaxan |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $83.37 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $72.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $71.27 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $66.96 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.92 | 2023-2025 | |
| Averitas Pharma INC. | $48.80 | 2023-2025 | Qutenza |
| Janssen Pharmaceuticals, INC | $48.21 | 2022-2023 | Spravato, Xarelto |
| Mylan Specialty L.P. | $45.23 | 2024 | Yupelri |
| Allergan, INC. | $44.22 | 2020 | |
| Grt US Holding, INC. | $41.21 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $41.14 | 2024-2025 | Ingrezza |
| Genentech USA, INC. | $39.99 | 2021-2025 | Ocrevus Zunovo |
| Tandem Diabetes Care, INC. | $32.23 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Roche Diagnostics Corporation | $30.72 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.52 | 2021-2022 | |
| Seqirus USA INC | $26.39 | 2024 | Fluad, Flucelvax |
| Inspire Medical Systems, INC. | $25.85 | 2025 | Inspire |
| Medtronic, INC. | $25.39 | 2022-2023 | Minimed 780g |
| Takeda Pharmaceuticals U.S.A., INC. | $24.56 | 2023 | Trintellix |
| Sumitomo Pharma America, INC. | $23.81 | 2025 | Gemtesa |
| Sanofi Pasteur INC. | $19.83 | 2019 | |
| Dexcom, INC. | $18.88 | 2024 | Dexcom G6 Transmitter |
| Radius Health, INC. | $18.18 | 2019 | |
| Exact Sciences Corporation | $17.88 | 2025 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $17.67 | 2023 | Amvuttra |
| Organon LLC | $17.24 | 2021 | |
| Viatris Specialty LLC | $17.15 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $16.11 | 2025 | Voquezna |
| Neurelis, INC. | $12.98 | 2023 | Valtoco |
| Quidel Corporation | $4.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Thayne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.